Remission and recovery in depression treatment

Drug Development Research

Volumn 65, Issue 4, 2005, Pages 335-343

  Trivedi, Madhukar H ^a   Kleiber, Beverly ^a   Greer, Tracy L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Major depressive disorder; Remission; Treatment algorithms

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE UPTAKE INHIBITOR; NEUROKININ; NEUROKININ ANTAGONIST; NEUROTRANSMITTER; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN 1A AGONIST; SEROTONIN 1D ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ALGORITHM; COST OF ILLNESS; DEPRESSION; HUMAN; MAJOR DEPRESSION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REMISSION; REVIEW; TREATMENT OUTCOME;

EID: 29544445541     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.20034     Document Type: Review

References (75)

1. Altar CA. 1999. Neurotrophins and depression. Trends Pharmacol Sci 20:59-61.
2. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. 2003. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiat 54:703-709.
3. Amsterdam JD, Hornig-Rohan M. 1996. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 19:371-386.
4. Aydemir O, Deveci A, Taneli F. 2005. The effect of chronic antidepressant treatment on serum brain-derived neurotropic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiat 29:261-265.
5. Beekman AT, Penninx BW, Deeg DJ, de Beurs E, Geerling SW, van Tilburg W. 2002. The impact of depression on the well-being, disability and use of services in older adults: a longitudinal perspective. Acta Psychiatr Scand 105:20-27.
6. Bielski RJ, Friedel RO. 1976. Prediction of tricyclic antidepressant response: a critical review. Arch Gen Psychiat 33:1479-1489.
7. Coppell AL, Pei Q, Zetterstrom TS. 2003. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44:903-910.
8. Crismon ML, Trivedi MH, Pigott TA, Rush AJ, Hirschfeld RMA, Kahn DA, DeBattista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME, Texas Consensus Conference Panel. 1999. The Texas Medication Project: Report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder. J Clin Psychiat 60:142-156.
9. Cnijpers P, de Graaf R, van Dorsselaer S. 2004. Minor depression: Risk profiles, functional disability, health care use and risk of developing major depression. J Affect Disord 79:71-79.
10. Depression Guideline Panel. 1993. Clinical Practice Guideline Number 5: Depression in primary care, vol. I. Detection and diagnosis. Rockville, MD: US Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy & Research (AHCH publication 93-0550).
11. Entsnah R, Derivan A, Kikta D. 1998. Early onset of antidepressant action of venlafaxine: Pattern analysis in intent-to-treat patients. Clin Ther 20:517-526.
12. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ. 2003. Background and rationale lor the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26:457-494.
13. Fogel J, Fanerbach JA, Ziegelstein RC, Bush DE. 2004. Quality of life in physical health domains predicts adherence among myocardial infarction patients even after adjusting for depressive symptoms. J Psychosom Res 56:75-82.
14. Gilbert DA, Altshnler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, Rush AJ. 1998. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiat 59:345-351.
15. Connl AS, Akdeniz F. Taneli F, Donat O, Eker C, Vahip S. 2005. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci (in press). DOI:10.1007/s00406-005- 0578-6; epub 6 April 2005.
16. Guze SB, Robins E. 1970. Suicide and primary affective disorders. Br J Psychiat 117:437-438.
17. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. 1995. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiat 52:11-19.
18. Herrman H, Patrick DL, Diehr P, Martin ML, Fleck M, Simon GE, Buesching DP. 2002. Longitudinal investigation of depression outcomes in primary care in six countries: The LIDO study. Functional status, health service use and treatment of people with depressive symptoms. Psychol Med 32:889-902.
19. Hirschield RM. 2001. Clinical importance of long-term antidepressant treatment. Br J Psychiat 179(Suppl 42):S4-S8.
20. Hunkeler EM, Meresman JF, Hargreaves WA, Fireman B, Berman WH, Kirsch PA, Groebe J, Hurt SW, Braden P, Getzell M, Feigenbaum PA, Peng T, Saltzer M. 2000. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med 9:700-708.
21. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. 2002. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiat Res 109:143-148.
22. Katon W, Von Korff M, Lin E, Unutzer J, Simon G, Walker E, Ludman E, Bush T. 1997. Population-based care of depression: Effective disease management strategies to decrease prevalence. Gen Hosp Psychiat 19:169-178.
23. Keller MB, Lavori PW. 1984. Double depression, major depression, and dysthymia: Distinct entities or different phases of a single disorder? Psychopharmacol Bull 20:399-402.
24. Keller MB, Lavori FW, Endicott J, Coryell W, Klerman GL. 1983. Double depression: two-year follow-up. Am J Psychiat 140:689-694.
25. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, Shea T. 1992. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 49:809-816.
26. Keller MB, Hirschfeld RM, Hanks D. 1997. Double depression: A distinctive subtype of unipolar depression. J Affect Disord 45:65-73.
27. Keller MR, Gelenberg AJ, Hirschfeld HM, Rush AJ, Thase ME, Kocsis JH, Markowitz JC, Fawcett JA, Koran LM, Klein DN, Russell JM, Kornstein SG, McCullough JP, Davies SM, Harrison WM. 1998. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiat 59:598-607.
28. Kessler KC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiat 51:8-19.
29. Kessler HC, Berglund P, Demler O, Jin B, Koretz D, Merikangas KH, Rush AJ, Walters EE, Wang PS, National Cormorbidity Survey Replication. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105.
30. Kleiber B, Jain S, Trivedi MH. 2005. Depression and pain: implications for symptomatic presentation and pharmacological treatments. Psychiatry 2:12-18.
31. Kocsis JH, Friedman RA, Markowitz JC, Leon AC, Miller NL, Gniwesch L, Parides M. 1996. Maintenance therapy for chronic depression: a controlled trial of desipramine. Arch Gen Psychiat 53:769-770.
32. Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RMA, LaVange LM, Keller MB. 2001. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 65:27-36.
33. Lin CF, Hedrick SC, Chaney EF, Heagerty P, Felker B, Hasanberg N, Fihn S, Katon W. 2003. Cost-effectiveness of collaborative care for depression in a primary care veteran population. Psychiatr Serv 54:698-704.
34. Lyons WE, Mamonnas LA, Ricaurte GA, Coppola V, Reid SW, Bora SH, Wihler C, Koliatsos VE, Tessarollo L. 1999. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci USA 96:15239-15244.
35. Mamounas LA, Blue ME, Siuciak JA, Altar CA 1995. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 15:7929-7939.
36. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, Markowitz JC, Schlager DS, Kornstein SG, Davis SM, Harrison WM, Keller MB. 1998. The treatment of chronic depression, part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiat 59:608-619.
37. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. 2003a. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiat 160:1830-1835.
38. Murphy GM, Kremer C, Rodrigues H, Schatzberg AF, Mitrazapine versus paroxetine Study Group. 2003b The apolipoprotein E ε4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol Psychiat 54:665-673.
39. Murphy Jr GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. 2004. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major expression. Arch Gen Psychiat 61:1163-1169.
40. Nibuya M, Morinobu S, Duman RS. 1995. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539-7547.
41. Nierenberg AA. 2001. Current perspectives on the diagnosis and treatment of major depressive disorder. Am J Manag Care 7(Suppl 11):S353-S366.
42. Ormel J, Oldenhinkel AJ, Nolen WA, Vollebergh W. 2004. Psychosocial disability before, during, and after a major depressive episode: A 3-wave population-based study of state, scar, and trait effects. Arch Gen Psychiat 61:387-392.
43. Pyne JM, Bullock D, Kaplan RM, Smith TL, Gillin JC, Golshan S, Kelsoe JR, Williams DK. 2001. Health-related quality-of-life measure enhances acute treatment response prediction in depressed inpatients. J Clin Psychiat 62:261-268.
44. Quitkin FM, McGrath PJ, Stewart JW, Deliyannides D, Taylor BP, Davies CA, Klein DF. 2005. Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. J Clin Psychiat 66:670-676.
45. Ranga K, Krishman B. 2002. Clinical experience with substance P receptor (NK1) antagonists in deppression. J Clin Psychiat 63(Suppl 11):25-29.
46. Regier DA, Narrow WF, Rae DS, Manderscheid BW, Locke BZ, Goodwill FK. 1993. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiat 50:85-94.
47. Rush AJ, Roffwarg HP, Giles DE, Schlesser MA, Fairchild C, Tarell J. 1983. Psychobiological predictors of antidepressant drug response. Pharmacopsychiatria 16:192-194.
48. Rush AJ, Trivedi MH, Schriger D, Petty F. 1992. The development of clinical practice guidelines for the diagnosis and treatment of depression. Gen Hosp Psychiat 14:230-236.
49. Rush AJ, Crismon ML, Toprae MG, Shon SS, Rago WV, Miller AL, Suppes T, Trivedi MH, Biggs MM, Shores-Wison K, Kashner TM, Altshuler KZ. 1999a. Implementing guidelines and systems of care: experiences with the Texas Medication Algorithm Project (TMAP). J Pract Psychiat Behav Health 5:75-86.
50. Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SS, Suppes T, Miller AL, Trivedi MH, Swann AC, Biggs MM, Shores-Wilson K, Kashuer TM, Pigott T, Chiles JA, Gilbert DA, Altshuler KZ. 1999b. Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. J Clin Psychiat 60:284-291.
51. Rush AJ, Trivedi M, Fava M. 2003. Depression IV STAR*D treatment trial for depression. [Images in Neuroscience]. Am J Psychiat 160:237.
52. Rush AJ, Fava M, Wisniewski SB, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G, STAH*D Investigators Group. 2004. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119-142.
53. Russo-Nenstadt AA, Chen MJ. 2005. Brain-derived neurotrophic factor and antidepressant activity. Circ Pharm Des 11:1495-1510.
54. Russo-Nenstadt AA, Alejandre H, Garcia C, Ivy AS, Chen MJ. 2004. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 29:2189-2199.
55. Serretti A, Benedetti F, Zanardi H, Smeraldi E. 2005. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiat 29:1074-1084.
56. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakira C, Nakazato M, Watanabe H, Shinoda N, Okada S-I, Iyo M. 2003. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54:70-75.
57. Sinciak JA, Boylan C, Fritsche M, Altar CA, Lindsay RM. 1996. BDNF increases monoaminergic activity in rat brain following intracerebroventricular or intraparenchymal administration. Brain Res 710:11-20.
58. Stahl SM. 2004. Essential psychopharmacology: neuroscientific basis and practical applications. 2nd ed. New York: Cambridge University Press.
59. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. 2003. Cost of lost productive work time among US workers with depression. JAMA 289:3135-3144.
60. Thase ME, Entsnah AR, Rudolph RL. 2001. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiat 178:234-241.
61. Trivedi MH, Baker SM. 2001. Clinical significance of monitoring early symptom change to predict outcome. J Clin Psychiat 62(Suppl 4):27-33.
62. Trivedi MH, DeBattista C, Fawcett J, Nelson C, Osser DN, Stein D, Jobson K. 1998. Developing treatment algorithms for unipolar depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP). Psychopharmacol Bull 34:355-359.
63. Trivedi MH, Rush AJ, Crismon L, Kashner TM, Toprac MG, Carmody TJ, Key T, Biggs MM, Shores-Wilson K, Witte B, Suppes T, Miller AL, Altshuler KZ, Shon SP. 2004. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiat 61:669-680.
64. Trivedi MH, Morris DW, Pan J, Crannemann BD, Rush AJ. 2005a. What moderator characteristics are associated with better prognosis for depression? Neuropsychiat Dis Treat 1:51-57.
65. Trivedi MH, Rush AJ, Wisniewski SR, Warden D, McKinney W, Downing M, Berman SR, Farabaugh A, Luther JF, Nierenberg AA, Lis J, Sackeim H. 2005b. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STARD report. J Clin Psychiat (in press).
66. Trivedi MH, Morris DW, Grannemann BD, Mahadli S. 2005e. Symptom clusters as predictors of late response to antidepressant treatment. J Clin Psychiat 66:1064-1070.
67. Unutzer J, Rubenstein L, Katon W, Tang L, Dnan N, Lagomasino IT, Wells KB. 2001. Two-year effects of quality improvement programs on medication management for depression. Arch Gen Psychiat 58:935-942.
68. Unutzer J, Katon W, Callahan CM, Williams Jr JW , Hunkeler E, Harpole L, Hoffing M, Della Penna HD, Noel PH, Lin EH, Arean PA, Hegel MD, Tang L, Belin TH, Oishi S, Langston C; IMPACT Investigators. Improving Mood-Promoting Access to Collaborative Treatment. 2002. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 288:2836-2845.
69. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. 2004. Global burden of depressive disorders in the year. Br J Psychiat 184:386-392.
70. Valenstein M, Vijan S, Zeber JE, Boehm K, Buttar A. 2001. The cost utility of screening for depression in primary care. Ann Intern Med 134:345-360
71. Wells KB, Sherbourne CD. 1990. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiat 56:897-904.
72. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware J. 1989. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 262:914-919.
73. Wells KB, Sturm R, Sherbourne CD, Meredith LS. 1996. Caring for depression. Cambridge, MA: Harvard University Press.
74. World Health Organization (WHO). 1996. The global burden of disease. In: Murray CJ, Lopez AD, editors. Boston: Harvard School of Public Health, World Bank.
75. World Health Organization (WHO). 2001. The World Health Report 2001, Mental Health: New Understanding, New Hope. Geneva: World Health Organization.